Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. (Source: Bloomberg)
📰 Original Source
Read full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.